Summary

[0007a] In one aspect, there is provided the use of a pharmaceutically acceptable co-suspension in the manufacture of a medicament for use in the treatment of asthma, COPD, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, respiratory distress syndrome, pulmonary hypertension, pulmonary inflammation experienced with cystic fibrosis, or pulmonary obstruction experienced with cystic fibrosis, wherein said pharmaceutically acceptable co-suspension is to be delivered to the patient twice daily as a respirable aerosol, and comprises:

a suspension medium comprising a pharmaceutically acceptable propellant,

a first species of respirable active agent particles comprising glycopyrrolate or a pharmaceutically acceptable salt, or isomer thereof,

a second species of respirable active agent particles comprising formoterol or a pharmaceutically acceptable salt, or isomer thereof,

one or more species of respirable suspending particles, wherein the first and second species of respirable active agent particles and the respirable suspending particles co-locate to form a co-suspension within the suspension medium,

wherein a therapeutically effective amount of the glycopyrrolate or pharmaceutically acceptable salt, or isomer thereof and formoterol or pharmaceutically acceptable salt, or isomer thereof, comprising no more than 150 µg of the glycopyrrolate or pharmaceutically acceptable salt, or isomer thereof and no more than 12 µg of the formoterol or pharmaceutically acceptable salt, or isomer thereof, is to be delivered to the patient at each administration and

wherein administering the co-suspension to the patient results in an increase in FEV_1 of at least 200mL within a period of time selected from 0.5 hours or less, 1 hour or less and 1.5 hours or less.

[0007b] In another aspect, there is provided a pharmaceutically acceptable co-suspension for use as defined herein, wherein between about 2 µg and about 5 µg of formoterol is to be delivered to the patient per actuation of the metered dose inhaler.